中国临床药学杂志

目的 比较肿瘤科与非肿瘤科抗肿瘤药物治疗的合理性及不良反应发生情况，为加强抗肿瘤合理用药体系建设提供参考。方法 以30%抽样比例，逐月提取2023年度我院抗肿瘤治疗病例，从药物剂量、方案选择、药物选择和溶媒选择等10个维度评估抗肿瘤药物使用的合理性，并从骨髓毒性、消化系统毒性、肝毒性、肾毒性等11个维度比较不良反应的发生情况。结果 肿瘤科在药物剂量、方案选择、药物选择、溶媒选择、给药时机、联合用药和预处理方案这7个方面均优于非肿瘤科（P<0.05）；在骨髓毒性、消化系统毒性、肝毒性、肾毒性和心脏毒性发生率这5个方面均优于非肿瘤科（P<0.05）。结论 非肿瘤科在合理用药和安全性管理方面存在显著不足，建议将肿瘤科和非肿瘤科统一纳入合理用药体系建设，以提升抗肿瘤的综合治疗水平。

AIM To compare the rationality of antineoplastic drug therapy and adverse reaction profiles between oncology and non-oncology departments, providing a reference for strengthening the construction of a rational drug use system for antineoplastic medications. METHODS Using a 30% sampling ratio, cases of antineoplastic treatment were extracted from our hospital in 2023 monthly. The rationality of antineoplastic drug use was assessed across 10 dimensions, including drug dosage, treatment plan selection, drug selection, diluent selection, and etc. Adverse reaction occurrences were compared across 11 aspects, including myelotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, and etc. RESULTS The oncology department was superior to the non-oncology department in 7 aspects of drug dose, regimen selection, drug selection, solvent selection, administration time, combination of drugs, and preconditioning regimen(P < 0.05), and in 5 aspects of incidence of myelotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, and cardiotoxicity(P < 0.05). CONCLUSION Non-oncology departments exhibit significant deficiencies in rational drug use and safety management. It is recommended to integrate oncology and non-oncology departments into the construction of a rational drug use system to enhance the level of comprehensive antineoplastic treatment.